Nanjing Huanglong Biotechnology Co., Ltd. announced that it will receive CNY 90,000,000 in an equity round of funding on December 23, 2022. The transaction will include participation from existing investor Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd to retain its 100% stake in the company. On closing, the registered capital of the company will increase from CNY 20,000,000 to CNY 110,000,000.

The transaction has been approved at the eleventh meeting of the eighth session of the board of directors of the investor.